Amplify BlueStar Israel Technology ETF (ITEQ)

In our clinic and research protocols focusing on cutting-edge medical devices and biotechnology, tracking regional hubs like Israel is essential. Looking at ITEQ's sector footprint, which covers medical devices alongside clean energy and cyber security across 59 holdings, gives us a useful proxy for venture-backed innovation that eventually trickles into institutional pipelines. However, when evaluating the underlying portfolio mechanics, the fund's heavy growth tilt requires a careful look at regulatory timelines for its healthcare components.

On our desk, looking at ITEQ through a market sentiment lens reveals a fascinating divergence. While the ETF recently posted a July pullback with a -6.3% monthly return, its long-term annualized performance metrics sit near 14.7% to 15.4%. Yet, we cannot ignore the friction points: the fund carries a negative Morningstar Medalist Rating and a lofty P/E ratio sitting at 71.24. Combined with an expense ratio of 0.75%, positioning here demands an appetite for both valuation premium and foreign political risk.

From a risk management standpoint, foreign investing always introduces layers of complexity that domestic-only allocators miss. For ITEQ, the prospectus explicitly calls out currency fluctuations, political uncertainty, and potential tracking error if a sampling approach is utilized. With $112.3 million in net assets and 1.8 million shares outstanding trading on NYSE Arca, liquidity is adequate for tactical allocations, but investors must respect the inherent volatility of a geographically concentrated, tech-heavy small-cap basket.